Literature DB >> 7571573

Screening for cancer. Is it worth it?

F J Meyers1.   

Abstract

A delay in diagnosing cancer is widely perceived to compromise severely a patient's chance of being cured. The unrealistic expectations of technology and of physicians' capabilities are inconsistent with modern knowledge of the natural history of cancer. Established and recent precepts in clinical oncology and tumor biology emphasize that inherent characteristics of a malignant neoplasm predict its dissemination, rather than a real or perceived delay in diagnosis. The processes of carcinogenesis and dissemination are more nearly simultaneous than sequential. Uncritical belief in the ability of most cancer screening techniques to provide cure through early detection may do more harm than good. Policy and efforts would be better directed to the primary prevention or reversal of preneoplasia and to improved therapy for established cancer.

Entities:  

Mesh:

Year:  1995        PMID: 7571573      PMCID: PMC1303022     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  7 in total

1.  Medical malpractice and the tort system.

Authors:  P D Jacobson
Journal:  JAMA       Date:  1989-12-15       Impact factor: 56.272

Review 2.  Molecular aspects of tumor cell invasion and metastasis.

Authors:  S Aznavoorian; A N Murphy; W G Stetler-Stevenson; L A Liotta
Journal:  Cancer       Date:  1993-02-15       Impact factor: 6.860

3.  High 10-year survival rate in patients with early, untreated prostatic cancer.

Authors:  J E Johansson; H O Adami; S O Andersson; R Bergström; L Holmberg; U B Krusemo
Journal:  JAMA       Date:  1992 Apr 22-29       Impact factor: 56.272

4.  Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume.

Authors:  H P Schmid; J E McNeal; T A Stamey
Journal:  Cancer       Date:  1993-03-15       Impact factor: 6.860

5.  A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team.

Authors:  C Fleming; J H Wasson; P C Albertsen; M J Barry; J E Wennberg
Journal:  JAMA       Date:  1993-05-26       Impact factor: 56.272

6.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.

Authors:  H B Carter; J D Pearson; E J Metter; L J Brant; D W Chan; R Andres; J L Fozard; P C Walsh
Journal:  JAMA       Date:  1992 Apr 22-29       Impact factor: 56.272

7.  Tumor biology in explanation of the failure of screening for cancer and in determination of future strategies.

Authors:  F J Meyers
Journal:  Am J Med       Date:  1986-05       Impact factor: 4.965

  7 in total
  1 in total

1.  Introduction.

Authors:  F Fitzgerald
Journal:  West J Med       Date:  1995-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.